Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tanya Simuni

Showing results (151-160 of 196) with videos related to

Pageof 20
Sort By:
Medrxiv : the Preprint Server for Health Sciences|December 23, 2024
Impact of dopamine deficiency and REM sleep behavior disorder on cognition in early neuronal synuclein disease with hyposmiaDaniel Weintraub, Anuprita R Nair, Ryan Kurth, et al.
Plos One|May 19, 2017
Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson diseaseChelsea Caspell-Garcia, Tanya Simuni, Duygu Tosun-Turgut, et al.
Neurology|January 13, 2026
CSF α-Synuclein Seed Amplification Assays and Skin Immunofluorescence: Clinical Applications, Research Opportunities, and Knowledge GapsDavid G Coughlin, Charles H Adler, William Barbosa, et al.
Annals of Neurology|May 14, 2026
Identification and Enrollment of Individuals Prior to Parkinson's Disease Diagnosis: Biomarker-Driven Adaptive Eligibility and Enrollment into the Parkinson's Progression Markers InitiativeEthan G Brown, Lana M Chahine, Roseanne D Dobkin, et al.
JMIR Research Protocols|August 27, 2025
Improving Prediction of Falls and Cognitive Impairment in Parkinson Disease: Protocol for a Decentralized Observational StudyAudrey Hoyt, Casey Dorney, Peggy Auinger, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|May 4, 2021
Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's DiseaseThomas Kremer, Kirsten I Taylor, Juliane Siebourg-Polster, et al.
The Lancet. Neurology|November 4, 2019
Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional studyTanya Simuni, Liz Uribe, Hyunkeun Ryan Cho, et al.
Annals of Neurology|July 11, 2025
Cognitive Performance in Early Neuronal Synuclein Disease with Hyposmia but without Motor Disability: Association with Dopamine Deficiency and Isolated Rapid Eye Movement Sleep Behavior DisorderDaniel Weintraub, Anuprita R Nair, Ryan Kurth, et al.
Annals of Clinical and Translational Neurology|December 15, 2020
Dopamine transporter imaging predicts clinically-defined α-synucleinopathy in REM sleep behavior disorderLana M Chahine, Michael C Brumm, Chelsea Caspell-Garcia, et al.
Frontiers in Neurology|October 18, 2021
A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline DataGennaro Pagano, Frank G Boess, Kirsten I Taylor, et al.
Pageof 20

Showing results (151-160 of 196) with videos related to

Sort By:
Pageof 20
Medrxiv : the Preprint Server for Health Sciences|December 23, 2024
Impact of dopamine deficiency and REM sleep behavior disorder on cognition in early neuronal synuclein disease with hyposmiaDaniel Weintraub, Anuprita R Nair, Ryan Kurth, et al.
Plos One|May 19, 2017
Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson diseaseChelsea Caspell-Garcia, Tanya Simuni, Duygu Tosun-Turgut, et al.
Neurology|January 13, 2026
CSF α-Synuclein Seed Amplification Assays and Skin Immunofluorescence: Clinical Applications, Research Opportunities, and Knowledge GapsDavid G Coughlin, Charles H Adler, William Barbosa, et al.
Annals of Neurology|May 14, 2026
Identification and Enrollment of Individuals Prior to Parkinson's Disease Diagnosis: Biomarker-Driven Adaptive Eligibility and Enrollment into the Parkinson's Progression Markers InitiativeEthan G Brown, Lana M Chahine, Roseanne D Dobkin, et al.
JMIR Research Protocols|August 27, 2025
Improving Prediction of Falls and Cognitive Impairment in Parkinson Disease: Protocol for a Decentralized Observational StudyAudrey Hoyt, Casey Dorney, Peggy Auinger, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|May 4, 2021
Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's DiseaseThomas Kremer, Kirsten I Taylor, Juliane Siebourg-Polster, et al.
The Lancet. Neurology|November 4, 2019
Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional studyTanya Simuni, Liz Uribe, Hyunkeun Ryan Cho, et al.
Annals of Neurology|July 11, 2025
Cognitive Performance in Early Neuronal Synuclein Disease with Hyposmia but without Motor Disability: Association with Dopamine Deficiency and Isolated Rapid Eye Movement Sleep Behavior DisorderDaniel Weintraub, Anuprita R Nair, Ryan Kurth, et al.
Annals of Clinical and Translational Neurology|December 15, 2020
Dopamine transporter imaging predicts clinically-defined α-synucleinopathy in REM sleep behavior disorderLana M Chahine, Michael C Brumm, Chelsea Caspell-Garcia, et al.
Frontiers in Neurology|October 18, 2021
A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline DataGennaro Pagano, Frank G Boess, Kirsten I Taylor, et al.
Pageof 20